- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Essilor's part in KBco
Essilor of America Inc. (EOA) has acquired a majority stake in KBco, one of the leading distributors of polarized lenses in the United States. KBco will operate as an independent subsidiary of EOA.
Dallas-Essilor of America Inc. (EOA) has acquired a majority stake in KBco, one of the leading distributors of polarized lenses in the United States. KBco will operate as an independent subsidiary of EOA. Its current management team will remain in place, including Kurt Hollinger, president, and John Olsen, chief operating officer.
"This acquisition will allow Essilor to expand our presence in the polarized segment of the industry. It will enhance our portfolio of products to support our customer base," said John Carrier, president of EOA. "KBco will continue with business as usual. We will work with Kurt Hollinger, John Olsen, and their management team to leverage Essilor's strength in product research and development, distribution, marketing, and financial resources."
"We believe that this acquisition will greatly benefit our customers and employees alike," said Hollinger. "Through this acquisition, Essilor and KBco will be able to utilize the strengths of both companies to help our customers build their businesses."
